ADRB2基因多态性对哮喘患者沙丁胺醇疗效影响的荟萃分析
本研究通过荟萃分析探讨ADRB2基因Arg16Gly和Gln27Glu多态性与哮喘患者使用沙丁胺醇后FEV1.0%变化的关系。共纳入7项研究,总体分析未发现显著关联,仅在特定亚组中观察到弱关联,提示证据有限且异质性显著。
要点
- 总体未发现ADRB2 Arg16Gly或Gln27Glu与沙丁胺醇后FEV1.0%显著相关。
- 在未行乙酰甲胆碱支气管收缩的研究中,Arg16Gly GG vs AA的FEV1.0%平均差为-3.92(95%CI -7.29至-0.54)。
- 在无合并症患者中,Arg16Gly GG vs GA的平均差为-1.93(95%CI -3.77至-0.10)。
核心结论
- 现有证据表明ADRB2 Arg16Gly和Gln27Glu与沙丁胺醇使用后FEV1.0%的关联证据较弱。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane对照试验中心注册库,纳入7项定量研究,采用逆方差加权法合并结果,PROSPERO注册号CRD42019074554。
主要发现
- 总体荟萃分析显示Arg16Gly和Gln27Glu各基因型间FEV1.0%平均差异无统计学意义。
- 亚组分析中,未行乙酰甲胆碱支气管收缩的研究里Arg16Gly GG vs AA的FEV1.0%平均差为-3.92(95%CI -7.29至-0.54;I2=0%)。
- 无合并症患者中Arg16Gly GG vs GA的平均差为-1.93(95%CI -3.77至-0.10;I2=0%)。
临床怎么用
- 不推荐常规根据ADRB2基因型预测沙丁胺醇疗效,临床决策仍需结合患者具体情况。
局限性
- 研究间存在显著异质性,需谨慎设计并考虑样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The associations of 2 nonsynonymous single nucleotide polymorphisms (Arg16Gly and Gln27Glu) in the adrenoceptor β2 (ADRB2) gene with response after albuterol use are conflicting. We conducted a meta-analysis to examine the cumulative evidence of the effects of these 2 variants on percent forced expiratory volume in 1 second (FEV1.0%) after albuterol use in asthma patients. METHODS: We conducted a comprehensive literature search using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials to identify studies examining the association between ADRB2 Arg16Gly and Gln27Glu and FEV1.0% shortly after albuterol administration. The individual study results were combined with weights based on the inverse variance method. This systematic review was registered in the PROSPERO (registration number: CRD42019074554). RESULTS: Among 273 initial studies identified, 7 studies met the inclusion criteria for quantitative evaluation. Results of the overall meta-analysis indicated no statistically significant mean difference of FEV1.0% between genotypes of Arg16Gly and Gln27Glu. In subgroup analyses, significant associations were found for Arg16Gly GG (vs AA) among studies where no methacholine bronchoconstriction was conducted (mean difference, -3.92; 95% confidence interval, -7.29 to -0.54; I2 = 0%), and for Arg16Gly GG (vs GA) among studies that included patients with no comorbidities (mean difference, -1.93; 95% confidence interval, -3.77 to -0.10; I2 = 0%). CONCLUSION: Synthesis of the studies to date shows weak evidence for an association between ADRB2 Arg16Gly and Gln27Glu and FEV1.0% after albuterol use, results of which underscore significant heterogeneity across studies and the need for careful design and sample size considerations.
引用
- Hikino K, Kobayashi S, Ota E, et al. A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma. Br J Clin Pharmacol. 2020. PMID: 32986886. doi:10.1111/bcp.14570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。